POST Online Media Lite Edition


Nordic Nanovector appoints Lisa Rojkjaer as chief medical officer

Staff Writer |
Oslo, Norway - November 16, 2016, Oslo, Norway - Nordic Nanovector ASA, a biotechnology company, announces that Lisa Rojkjaer has joined the company as chief medical officer and as a member of the executive management team.

Article continues below

Dr. Rojkjaer is a board-certified haematologist with more than 15 years of global and regional clinical development and medical affairs expertise in the biotech and pharma industries, and has extensive experience in the development of both biologics and small molecules in haematology and immunology.

Dr. Rojkjaer joins Nordic Nanovector from Novartis Pharmaceuticals where she held the position of Global Clinical Program Head, Oncology Global Development.

Her previous roles also include CMO at Molecular Partners (Switzerland), Vice President, Head of Clinical Development at Morphosys AG (Germany), and Head of Global Medical Affairs, Biopharmaceuticals and Director of Clinical Development, Hematology in the US for Novo Nordisk.


Cermaq makes senior management appointments
Targovax appoints Damian Marron as chairman
Aker Solutions appoints Ole Martin Grimsrud as CFO
Aker BP appoints Marit Blaasmo as senior vice president
Targovax appoints Oystein Soug as CEO

What to read next

Bavarian Nordic appoints James B. Breitmeyer as executive vice president
Lisa Montague appointed chief executive officer of Loewe
Studsvik appoints new CFO